Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the latest status of its ongoing phase IIb psilocybin therapy trial. The trials are being conducted to test the efficacy of psilocybin against treatment-resistant depression.
A total of 216 patients have now completed the administration of psilocybin under the clinical trial, marking the largest psilocybin trial to date while also closing the enrollment period for the program. The actual number of patients under the trial sits at 230 however as a result of several not yet receiving their dosage of psilocybin yet, but yet have enrolled in the program.
After dosage, patients will be followed-up on for a period of 12 weeks as the company monitors the effects of the psilocybin session. Patients were randomly dosed with either a 25mg, 10mg, or 1mg dose of the compound as the firm looks to measure the impact of the separate dosages as the company works to find a solution for treatment-resistant depression.
Data is expected to be reported in late 2021 from the trial, with phase III trials expected to get underway as soon as the regulatory support to do so is provided.
Compass Pathways last traded at $14.07 on the NYSE.
Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
